A Boston-based investment group that provides funding to early-stage life science and healthcare companies.

Sky Ventures Group

UM Ventures is a joint initiative of the University of Maryland, Baltimore and the University of Maryland, College Park to commercialize technologies and expand industry collaboration by engaging partners in industry and social ventures. By engaging directly with external partners, it will bring new investment, expanded markets, and more startup ventures.

UM Ventures

New York Angels is one of the largest and most active angel investment organizations.  Founded in 2004 as the successor organization to the NYNMA (New York New Media Association) Angel Investor Program, New York Angels is a membership organization of over 110 active angel investors and early stage venture capital funds. The group meets monthly to screen and present early stage technology companies, and its members have invested over $100 million since 2002 into over 90 ventures. In April of 2017, PItchbook identified New York Angels as #3 in their list of the 8 top VCs funding seed rounds of New York-based companies.  Among the NYA membership are nationally known angel investors including Esther Dyson and David S. Rose. The group has one full-time staff, reporting to an 11 person Board of Directors chaired by Brian S. Cohen. Dr. Elizabeth Lindsey is currently Program Director of New York Angels. Since 2012, the membership has increased by 66% and investment activity has grown by over 215%.   New York Angels concentrates on early stage investments in the range of $100,000 - $1,000,000, although it has led deals as large as $2 million. It receives over 2,200 financing applications annually, from which it selects 12-16 companies each month for an in-person screening, where all members of New York Angels are invited to attend. The group meets again for an Investment Breakfast at the end of the month, where 2-4 opportunities present to the membership with a goal to close their current investment round within two months. The group is considered a leader in the growing field of organized angel investing. It was the first member of the national Angel Capital Association, hosted the ACA Summit conference in 2006, and was the initial test group for the now-standard gust (Angelsoft) funding platform.  Membership as an investor in New York Angels is by invitation only, and members are required to commit to investing at least $50,000 annually in early stage technology deals, in addition to the group's $3,500 annual membership dues.  Requests for funding for entrepreneurial ventures may be self-submitted through the group's website. New York Angels charges no fees to entrepreneurs.

New York Angels

Robin Hood Ventures is a group of angel investors, focused on early-stage, high-growth companies in the Greater Philadelphia region. We help entrepreneurs build great companies, providing capital, mentoring, expertise and connections to help companies reach their potential. Robin Hood generally invests $250k to $500k, and collaborates with angels, institutions and VCs in our network. We invest as a single entity in businesses we know and understand, in a way that gets deals done. Since 1999, we have invested in over 45 companies in industries including software, medical devices, biotech, internet and financial technology.

Robin Hood Ventures

TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State.   TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy.   In Maryland and beyond, TEDCO is a resource of mentoring, funding and networking for entrepreneurs and start-ups that need guidance as they bring innovative concepts to market.   TEDCO is more than an early stage funding resource. It is the hub of Maryland’s entrepreneurial network where startups find mentors, organizational assistance, facilities for daily operations, and a roadmap for success.

TEDCO

FFI fund

Propel(x) is an angel investing platform focused on funding early-stage companies that are built around scientific discovery.  The company is driven by a mission to help propel mankind by enabling investments in technologies that matter.  Propel(x) was founded in 2014 and is headquartered in San Francisco, California.

Propel(X)

Medcura

Medcura develops an advanced wound care platform designed to be used across a broad spectrum of clinical and non-clinical setups.

Medcura is a life science and medical device company that has developed a proprietary biomaterial platform to create a novel hemostasis portfolio of products designed for bleeding management. The company's technology utilizes natural, hydrophobically modified biomaterials that achieve hemostasis by mechanically coating the bleeding site via the process of mucoadhesion. Medcura's products are engineered to provide safe, effective, and lower-cost bleeding control solutions, with the potential to offer cost savings to healthcare providers and payers.

Medcura: The Future of Bleeding Control Is Now

TEDCO invests first $1M of Md.'s SSBCI funds in Medcura

Maryland’s Medcura raises $7.4M Series A for products that stop bleeding, treat wounds

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Medcura Names New Surgical Scientific Advisory Board

Medcura is a life science and medical device company that has developed a proprietary biomaterial platform to create a novel hemostasis portfolio of products designed for bleeding management. The company's technology utilizes natural, hydrophobically modified biomaterials that achieve hemostasis by mechanically coating the bleeding site via the process of mucoadhesion. Medcura's products are engineered to provide safe, effective, and lower-cost bleeding control solutions, with the potential to offer cost savings to healthcare providers and payers.
One of Medcura's key offerings is a consumer-facing product called Rapid-Seal, developed in partnership with first aid product manufacturer ASO. Rapid-Seal, a gel formulation, is designed to stop bleeding and create an antibacterial environment to promote wound healing. In July 2021, the product became available online and through a leading US drugstore chain.
Medcura is also developing advanced surgical products, including LifeFoam, designed for internal traumatic and military injuries. LifeFoam received breakthrough device designation from the US Food and Drug Administration in 2021. Additionally, the company is working on LifeGel, intended for use during routine surgical procedures.
In April 2020, Medcura opened a facility in the University of Maryland's Discovery District, where it manufactures its core ingredient and holds intellectual property and regulatory clearances. The company raised USD 7.4 million in a Series A financing round in August 2021 to support product development and team expansion.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Medcura

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless